A remarkable reduction in interstitial fluid volume in combination therapy with SGLT2 inhibitors and conventional diuretics is useful for ameliorating interstitial fluid retention in patients with congestive heart failure, renal interstitial congestion, and ascites of liver cirrhosis. Here, SLC5A2 is linked to congestive heart failure.